XBIT XBiotech Inc.

17.02
0  -1%
Previous Close 17.17
Open 17.35
Price To book 9.49
Market Cap 598.22M
Shares 35,148,000
Volume 221,137
Short Ratio 54.89
Av. Daily Volume 117,434

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 16, 2017.
MABp1
Hidradenitis Suppurativa (HS)
Noted November 2016 that Phase 2 trial has been completed and data is being finalized. Noted mid-March 2017 that data will be available soon. BPC estimate is for data release 2Q 2017.
Xilonix
Pyoderma Gangrenosum
Phase 1/2 top-line data released April 3, 2017. 4 patient deaths noted.
514G3
Staphylococcus Aureus Bacteremia
Phase 3 interim analysis announced February 21, 2017 - trial to continue as planned.
Xilonix
Colorectal cancer